Caustic ingestion: a risk-based algorithm. Tosca J, Sanchez A, Sanahuja A, Villagrasa R, Poyatos P, Mas P, Pascual I, Lluch P, Herreros B, Pena A, Sanchiz V, Minguez M. American Journal of Gastroenterology. 2022 Oct 1;117(10):1593-1604. doi: 10.14309/ajg.0000000000001953. PMID: 36194047

Correction to: Multicenter study of lumen-apposing metal stents with or without pigtail in endoscopic ultrasound-guided biliary drainage for malignant obstruction-BAMPI TRIAL: an open-label, randomized controlled trial protocol. Garcia-Sumalla A, Loras C, Sanchiz V, Sanz R, Vazquez-Sequeiros E, Aparicio J, de la Serna-higuera C, Luna-Rodriguez D, Andujar X, Capilla M, Barbera T, Foruny-Olcina J, Martinez B, Dura M, Salord S, Laquente B, Tebe C, Videla S, Perez-Miranda M, Gornals J, Spanish Working Grp Endoscopic. Trials. 2022 Mar 14;23(1):214. doi: 10.1186/s13063-022-06138-7. PMID: 35287708

Correction: Chaparro et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. J. Clin. Med. 2021, 10, 2885. Chaparro et al.; on behalf of the EpidemIBD Study Group of Geteccu. Journal of Clinical Medicine. 2022 Sep 30;11(19):5816. doi: 10.3390/jcm11195816. PMID: 36233844

Ferric carboxymaltose improves the quality of life of patients with inflammatory bowel disease and iron deficiency without anaemia. Huguet J, Cortes X, Bosca-Watts M, Munoz M, Maroto N, Iborra M, Hinojosa E, Capilla M, Asencio C, Amoros C, Paredes J. Journal of Clinical Medicine. 2022 May 15;11(10):2786. doi: 10.3390/jcm11102786. PMID: 35628914

Immigrant IBD patients in Spain are younger, have more extraintestinal manifestations and use more biologics than native patients. Gutierrez A, Zapater P, Ricart E, et al. Frontiers in Medicine. 2022 Feb 1;9:823900. doi: 10.3389/fmed.2022.823900. PMID: 35178413

Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430

Inflammatory capacity of exosomes released in the early stages of acute pancreatitis predicts the severity of the disease. Carrascal M, Areny-Balaguero A, de-Madaria E, Cardenas-Jaen K, Garcia-Rayado G, Rivera R, Martin Mateos R, Pascual-Moreno I, Gironella M, Abian J, Closa D. The Journal of pathology. 2022 Jan;256(1):83-92. doi: 10.1002/path.5811. PMID: 34599510

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Long-term real-world effectiveness and safety of ustekinumab in Crohn’s disease patients: the SUSTAIN Study. Chaparro M, Baston-Rey I, Fernandez-Salgado E, Gonzalez Garcia J, Ramos L, Diz-Lois Palomares M, Arguelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Nunez Ortiz A, Charro M, Ginard D, Duenas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutierrez Casbas A, Ramirez de la Piscina P, Bosca-Watts M, Arroyo M, Garcia M, Hinojosa E, Gordillo J, Martinez Montiel P, Velayos Jimenez B, Quilez Ivorra C, Vazquez Moron J, Maria Huguet J, Gonzalez-Lama Y, Munagorri Santos A, Amo V, Martin-Arranz M, Bermejo F, Martinez Cadilla J, Rubin de Celix C, Fradejas Salazar P, San Roman A, Jimenez N, Garcia Lopez S, Figuerola A, Jimenez I, Martinez Cerezo F, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernandez Camba A, Garcia-Alonso F, Van Domselaar M, Pajares Villarroya R, Nunez A, Rodriguez Moranta F, Marin-Jimenez I, Robles Alonso V, Martin Rodriguez M, Camo-Monterde P, Garcia Tercero I, Navarro Llavat M, Arias Garcia L, Hervias Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert J. Inflammatory Bowel Diseases. 2022 Nov 2;28(11):1725-1736. doi: 10.1093/ibd/izab357. PMID: 35166347

Management of patients with Intestinal Bowel Disease and COVID-19: a review of current evidence and future perspectives. Suria C, Bosca-Watts MM, Navarro P, Tosca J, Anton R, Sanahuja A, Revaliente M, Minguez M. Gastroenterologia y Hepatología. 2022 May;45(5):383-389. doi: 10.1016/j.gastrohep.2021.06.005. PMID: 34171421

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Ballester M, Gallego J, Fiorillo A, Casanova-Ferrer F, Gimenez-Garzo C, Escudero-Garcia D, Tosca J, Rios M, Monton C, Durban L, Ballester J, Benlloch S, Urios A, San-Miguel T, Kosenko E, Serra M, Felipo V, Montoliu C. Scientific Reports. 2022 Feb 14;12(1):2463. doi: 10.1038/s41598-022-06416-z. PMID: 35165326

Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA Registry. Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, et al. Journal of Clinical Medicine. 2022 Jan 14;11(2):421. doi: 10.3390/jcm11020421. PMID: 35054116

Risk factors for COVID-19 in inflammatory bowel disease: a national, ENEIDA-based case-control study (COVID-19-EII). Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, P Gisbert J, Mesonero F, Benitez O, Taxonera C, Ponferrada-Diaz A, Piqueras M, J Lucendo A, Caballol B, Manosa M, Martinez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Mancenido N, Martinez-Perez T, Lopez A, Rodriguez-Gutierrez C, Garcia-Lopez S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Perez Calle J, Busquets D, Perez-Martinez I, Navarro-Llavat M, Hernandez V, Arguelles-Arias F, Ramirez Esteso F, Meijide S, Ramos L, Gomollon F, Munoz F, Suris G, Ortiz de Zarate J, Huguet J, Llao J, Garcia-Sepulcre M, Sierra M, Dura M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutierrez A, Varela P, Rull N, Gilabert P, Hernandez-Camba A, Brotons A, Ginard D, Sese E, Carpio D, Aceituno M, Cabriada J, Gonzalez-Lama Y, Jimenez L, Chaparro M, Lopez-San Roman A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastian S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galan H, Pajares R, Olcina P, Manzano P, Domenech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu. Journal of Clinical Medicine. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540. PMID: 36556155

Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn’s disease (ProtDilat study): an open-label, multicentre, randomised trial. Loras C, Andujar X, Gornals JB, Sanchiz V, Brullet E, Sicilia B, Martin Arranz MD, Naranjo A, Barrio J, Duenas C, Foruny JR, Busquets D, Monfort D, Pineda JR, Gonzalez Huix F, Perez Roldan F, Pons V, Gonzalez B, Reyes Moreno J, Sainz E, Guardiola J, Bosca Watts MM, Fernandez Banares F, Mayor V, Esteve M. Lancet. Gastroenterology & Hepatology. 2022 Apr;7(4):332-341. doi: 10.1016/S2468-1253(21)00386-1. PMID: 35065738

Subcutaneous Infliximab [CT-P13], a true biologic 2.0. real clinical practice multicentre study. Huguet JM, Garcia-Lorenzo V, Marti L, Paredes JM, Ramirez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, Sanchis L, Perez GA, Bosca-Watts MM. Biomedicines. 2022 Aug 30;10(9):2130. doi: 10.3390/biomedicines10092130. PMID: 36140230

Thiopurine adherence: high prevalence with low impact in UC outcomes. Gomez-Medina C, Capilla-Lozano M, Ballester Ferre M, Marti-Aguado D, Crespo A, Bosca-Watts M, Navarro Cortes P, Anton R, Pascual Moreno I, Tosca Cuquerella J, Minguez Perez M. Revista Española de Enfermedades Digestivas. 2022 Feb;114(2):76-82. doi: 10.17235/reed.2021.7630/2020. PMID: 33733802

Using interpretable machine learning to identify baseline predictive factors of remission and drug durability in crohn’s disease patients on ustekinumab. Chaparro M, Baston-Rey I, Salgado E, Garcia J, Ramos L, Palomares M, Arguelles-Arias F, Flores E, Cabello M, Iturria S, Ortiz A, Charro M, Ginard D, Sadornil C, Ochoa O, Busquets D, Iyo E, Casbas A, de la Piscina P, Bosca-Watts M, Arroyo M, Garcia M, Hinojosa E, Gordillo J, Montiel P, Jimenez B, Ivorra C, Moron J, Huguet J, Gonzalez-Lama Y, Santos A, Amo V, Arranz M, Bermejo F, Cadilla J, de Celix C, Salazar P, San Roman A, Jimenez N, Garcia-Lopez S, Figuerola A, Jimenez I, Cerezo F, Taxonera C, Varela P, de Francisco R, Monfort D, Arriero G, Hernandez-Camba A, Alonso F, Van Domselaar M, Pajares-Villarroya R, Nunez A, Moranta F, Marin-Jimenez I, Alonso V, Rodriguez M, Camo-Monterde P, Tercero I, Navarro-Llavat M, Garcia L, Cruz D, Kloss S, Passey A, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert J. Journal of Clinical Medicine. 2022 Aug 3;11(15):4518. doi: 10.3390/jcm11154518. PMID: 35956133

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Algaba A, Guerra I, Ricart E, Iglesias E, Manosa M, Gisbert J, Guardiola J, Minguez Pérez M, Castro B, de Francisco R, Nos P, Bertoletti F, Mesonero F, Barrio J, Dolores Martin-Arranz M, Calvet X, Garcia-Lopez S, Sicilia B, Alcain G, Esteve M, Marquez L, Piqueras M, Jimenez L, Perez-Calle J, Bujanda L, Garcia-Sepulcre M, Fernandez A, Moraleja I, Humberto Lorente R, Garcia-Bosch O, Lamban A, Blazquez I, Rodriguez E, Huguet J, Lucendo A, Almela P, Busquets D, Ramirez de la Piscina P, Perez M, Domenech E, Bermejo F, Spanish GETECCU Grp, ENEIDA Project. Digestive Diseases and Sciences. 2021 Jun;66(6):2014-2023. doi: 10.1007/s10620-020-06424-x. PMID: 32671587

Patient-evaluated quality of care is related to better inflammatory bowel disease outcomes: the IQCARO II Project. Calvet X, Casellas F, Saldana R, Carpio D, Minguez M, Vera I, Marin L, Julia B, GETECCU G. Patient. 2021 Sep;14(5):625-634. doi: 10.1007/s40271-021-00500-8. PMID: 33709214

Risk factors and management strategies associated with non-response to aminosalicylates for maintenance treatment in ulcerative colitis. Marti-Aguado D, Ballester M, Minguez M. Revista Espanola de Enfermedades Digestivas. 2021 Jun;113(6):447-453. doi: 10.17235/reed.2021.7797/2021. PMID: 33569968

Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. Calafat M, Manosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, Lopez-SanRoman A, Guardiola J, Taxonera C, Minguez M, Martin-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, Garcia-Lopez S, Marquez L, Gomollon F, Barrio J, Esteve M, Munoz F, Gisbert JP, Gutierrez A, Hinojosa J, Arguelles-Arias F, Busquets D, Bujanda L, Perez-Calle JL, Sicilia B, Merino O, Martinez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodriguez C, Garcia-Sepulcre MF, Monfort D, Canete F, Domenech E. Journal of Crohn’s & Colitis. 2021 Dec 3;jjab213. doi: 10.1093/ecco-jcc/jjab213. PMID: 34864947

Surgical treatment of an intraductal papillary mucinous neoplasm of the biliary tract diagnosed by SpyGlass®. Martí Fernandez R, Garces Albir M, Ballester Ferre M, Dorcaratto D, Villagrasa Manzano R, Muñoz Forner E, Gómez Adrián J, Sanchiz Soler V, Sabater Orti L, Ortega Serrano J. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2021 Jan;113(1):45-47. doi: 10.17235/reed.2020.7122/2020. doi: 10.17235/reed.2020.7122/2020. PMID: 33054282

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. Chaparro M, Garre A, Mesonero F, Rodriguez C, Barreiro-de Acosta M, Martinez-Cadilla J, Arroyo M, Mancenido N, Sierra-Ausin M, Vera-Mendoza I, Casanova M, Nos P, Gonzalez-Munoza C, Martinez T, Bosca Watts M, Calafat M, Busquets D, Girona E, Llao J, Martin-Arranz M, Piqueras M, Ramos L, Suris G, Bermejo F, Carbajo A, Casas-Deza D, Fernandez-Clotet A, Garcia M, Ginard D, Gutierrez-Casbas A, Hernandez L, Lucendo A, Marquez L, Merino-Ochoa O, Rancel F, Taxonera C, Lopez Sanroman A, Rubio S, Domenech E, Gisbert J. Journal of Crohn’s & Colitis. 2021 Jan 13;15(1):35-42. doi: 10.1093/ecco-jcc/jjaa145. PMID: 32969471

Transjugular intrahepatic portosystemic shunt reduces hospital care burden in patients with decompensated cirrosis. Ballester M, Lluch P, Gomez C, Capilla M, Tosca J, Marti-Aguado D, Guijarro J, Minguez M. Internal and Emergency Medicine. 2021 Sep;16(6):1519-1527. doi: 10.1007/s11739-020-02602-x. PMID: 33400160

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. ESMO Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients. Lluch P, Segarra G, Tosca J, Navarro L, Navarrete-Navarro J, Herrera G, Sanahuja A, Hernandez S, Lluch S, Medina P. Anticancer Research. 2020 Dec;40(12):6853-6861. doi: 10.21873/anticanres.14707. PMID: 33288577

Patients with Inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. Allocca M, Chaparro M, Gonzalez H, Bosca Watts M, Palmela C, D’Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris G, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert J, Danese S, Fiorino G. Journal of Clinical Medicine. 2020 Oct 31;9(11):3533. doi: 10.3390/jcm9113533. PMID: 33142843

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Iborra M, Garcia-Morales N, Rubio S, Bertoletti F, Calvo M, Taxonera C, Bosca Watts M, Sierra M, Mancenido N, Beltran B, Castillejo O, Garcia-Planella E, Vera I, Alba C, Marti Aguado D, Ballester Ferre M, Cano-Sanz N, Pajares-Villarroya R, Cerrillo E, Canada A, Nos P. Scientific Reports. 2020 Oct 20;10(1):17774. doi: 10.1038/s41598-020-73577-0. PMID: 33082359

Recommendations of the Crohn’s Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn’s disease. Toledo Bosca M, Alos R, Maroto N, Gisbert J, Beltran B, Chaparro M, Nos P, Minguez Pérez M, Hinojosa J. Gastroenterologia y Hepatologia. 2020 Mar;43(3):155-168. doi: 10.1016/j.gastrohep.2019.09.012. PMID: 31870681

Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis. Ginard D, Marin-Jimenez I, Barreiro-de Acosta M, Ricart E, Domenech E, Gisbert J, Esteve M, Minguez Pérez M, Representacion GETECCU. Gastroenterologia y Hepatologia. 2020 Feb;43(2):97-105. doi: 10.1016/j.gastrohep.2019.10.004. PMID: 31839219

Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA registry. Calafat M, Manosa M, Mesonero F, Guardiola J, Minguez Pérez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert J, Calvet X, Garcia-Lopez S, Monfort D, Perez Calle J, Riestra S, Gomollon F, Garcia-Planella E, Bermejo F, Vicent H, Martin-Arranz M, Gutierrez A, Torres P, Canete F, Domenech E. Journal of Crohn’s & Colitis. 2020 Sep 16;14(9):1290-1298. doi: 10.1093/ecco-jcc/jjaa055. PMID: 32201893

The development of type-1 autoimmune hepatitis after chronic hepatitis C (HCV) clearance by direct-acting antivirals (DAA). Rodriguez C, Garcia A, Moreno I. Revista Espanola de Enfermedades Digestivas. 2020 Aug;112(8):664-665. doi: 10.17235/reed.2020.6785/2019. PMID: 32686431